Herombopag is a second-generation nonpeptide TpoR agonist that was developed first by Jiangsu Hengrui pharmaceutical by structural modification of eltrombopag to improve potency.156 Herombopag has the same mechanism of action as eltrombopag but with greater potency as evidenced by both in vitro and in vivo experiments.157,158 According to the national medical products administration, herombopag has received it is first approval in China as a treatment for chronic ITP that is refractory to immunotherapy and as a conditional approval for the treatment of aplastic anemia. Here, MPL is linked to aplastic anemia.